Jafra Cosmetics International
This article was originally published in The Rose Sheet
Net sales up 2% to $98.1 mil. in second quarter, led by gains of 16% and 11%, respectively, in the U.S. and Europe. Sales in U.S. Hispanic market advanced 19% year-to-date, Westlake Village, Calif.-based direct seller noted. Domestic increase was attributed to productivity-based changes in the selling program and new products. Local currency sales in Mexico, the firm's largest market, were flat for the period. Net income doubled during the quarter to $4 mil., reflecting higher operating profits and a lower effective tax rate. Jafra owner Clayton Dubilier & Rice seeking purchase offers for the cosmetics business, which had 2001 sales of $380 mil. and net income of $15.8 mil. A CDR-managed fund bought Jafra from Gillette in 1998...
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.